Delivery Order SPE2DB20D1004-SPE2DB25FNJXF
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,961.21 to AmerisourceBergen Drug Corp for the supply of Jardiance 10 mg tablets (90-count packages) on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed price delivery order represents a competitively awarded, non-set-aside contract with performance at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order on August 19, 2025, for supply of Jardiance 10 mg tablets in quantities of 90 units, with a ceiling value of $62,283.78 and firm fixed pricing. This non-set-aside, competitively awarded contract is scheduled for completion by August 20, 2025, with performance at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order falls under the company's substantial Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $12,130.81 on July 31, 2025, for the supply of Jardiance 25 mg tablets (90-count units). This firm fixed-price, competitively awarded contract has an ultimate completion date of August 1, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $1,658.26 delivery order to AmerisourceBergen Drug Corp for 90 tablets of Jardiance 25 mg on September 23, 2025, with completion scheduled for September 24, 2025. This is a firm fixed-price, non-set-aside contract for pharmaceutical delivery to support federal medical procurement needs. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $17,796.50 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count packages) on July 21, 2025, with an ultimate completion date of July 22, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at...
- The Defense Logistics Agency awarded a delivery order valued at $11,377.52 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count units) on September 18, 2025, with completion scheduled for September 19, 2025. This firm fixed price, non-set-aside contract reflects a routine pharmaceutical procurement supporting federal medical supply requirements. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Jardiance 25 mg tablets (90-count packages) valued at $10,494.63. The contract is a firm fixed price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,446.65 delivery order on August 4, 2025, for the supply of Jardiance 25 mg tablets (90-count). This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by August 5, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a continuation of AmerisourceBergen's substantial pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $22,670.24 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count units) on June 12, 2025, with a completion date of June 13, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and designates AmerisourceBergen's Conshohocken, Pennsylvania location as the place of performance. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order valued at $37,169.95 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count) on September 10, 2025, with completion targeted for September 11, 2025. The contract employs firm fixed-price pricing with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued...
- SPE2DB20D1004Indefinite Delivery Contract
- SPE2DB20D1004-SPE2DB25FNJXFDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $5,249.72 for 90-count packages of Jardiance 10 mg tablets on August 6, 2025, with completion scheduled for August 7, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, issued under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The work will be performed at the company's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp serves as a major pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. This delivery order for Jardiance, a diabetes medication, represents routine pharmaceutical fulfillment under the company's comprehensive $999.999 billion IDC with DLA Troop Support Medical (contract SPE2DX), which extends through December 2026 and enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company's federal contract portfolio demonstrates consistent capability in meeting competitive procurement requirements across diverse therapeutic domains including specialty medications, vaccines, and medical devices.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.2k | 8/6/25 |